ByInvesting.com • Feb 12, 2019 FDA accepts Xeris Pharma's application for glucagon rescue pen, action date June 10, 2019 The FDA accepts for review Xeris Pharmaceuticals ' (XERS -0.3% ...

On Friday, H.C. Wainwright raised the price target on Xeris Pharmaceuticals (NASDAQ:XERS) shares to $8.00 from $6.60, while ...

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA's decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC).

At close: April 4 at 4:00:01 PM EDT ...